HGH Fragment 176-191 vs Oxyntomodulin
Head-to-head comparison of HGH Fragment 176-191 (Human Growth Hormone Fragment 176-191) and Oxyntomodulin (Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HGH Fragment 176-191 | Oxyntomodulin |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Human Growth Hormone Fragment 176-191 | Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide |
| Molecular Weight | 1817.12 g/mol | ~4,200 Da |
| Half-Life | ~30 minutes | 12-15 minutes |
| Amino Acids | 16 | 37 |
| Typical Dose | — | Research doses vary; commonly 100-300 mcg in small human studies |
| Route | — | Subcutaneous/IV |
| Purity | >98% | ≥98% |
| Studies Count | 45 | 80 |
| Research Status | Active Research | Clinical |
HGH Fragment 176-191 Benefits
- ✓Targeted fat loss, no blood sugar impact, no IGF-1 elevation, inhibits lipogenesis, stimulates lipolysis, improved body composition
Oxyntomodulin Benefits
- ✓reduces appetite
- ✓increases satiety
- ✓supports weight loss
- ✓improves postprandial metabolic signaling
HGH Fragment 176-191 Dosing
250-500 mcg subcutaneously 1-2 times daily on empty stomach. 12-16 week cycles typical in research.
Oxyntomodulin Dosing
Research-only dosing|Subcutaneous or IV administration in trials|Pair with calorie restriction and monitoring
HGH Fragment 176-191 Side Effects
- ⚠Injection site irritation, headache, drowsiness. Does not affect blood sugar, insulin sensitivity, or elevate IGF-1.
Oxyntomodulin Side Effects
- ⚠nausea
- ⚠GI discomfort
- ⚠decreased appetite beyond target
Research Overview
HGH Fragment 176-191
This 16-amino-acid fragment specifically targets adipose tissue via beta-3 adrenergic receptors. Works through a GH-receptor-independent pathway, explaining selective fat-loss properties without growth-promoting effects.
Oxyntomodulin
Human studies showed acute reductions in food intake and modest weight loss, helping establish the GLP-1 and glucagon co-agonism concept. It remains a foundational peptide for obesity and satiety research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.